CBOE · OVLU
Invesco Russell 1000 Value Factor ETF
$30.09-$0.06 (-0.2%)
Invesco Russell 1000 Value Factor ETF’s quoted price sits in the lower half of its reported 52-week range, 0.04% below the high.
Loading market information…
NASDAQ · CNCR · USD
Stock price, dividends
Quote as of Sep 4, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Loncar Cancer Immunotherapy ETF’s quoted price sits in the lower half of its reported 52-week range, 44.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Loncar Cancer Immunotherapy ETF’s forward annual dividend is $1.85 per share, paid annual. The forward yield is 20.55% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this benchmark index. A minimum of 80% of the fund's overall holdings will consistently be directed towards these specific index components. Notably, this fund operates as a non-diversified investment vehicle.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Nov 1, 2026, 05:58 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
$30.09-$0.06 (-0.2%)
Invesco Russell 1000 Value Factor ETF’s quoted price sits in the lower half of its reported 52-week range, 0.04% below the high.
$28.55-$0.01 (-0.03%)
Hartford Multifactor Low Volatility US Equity ETF’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
$47.02+$0.42 (+0.91%)
Direxion MSCI Defensives Over Cyclicals ETF’s quoted price sits in the upper half of its reported 52-week range, 13.11% below the high.
$27.46-$0.04 (-0.14%)
Invesco Russell 1000 Yield Factor ETF’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$26.84+$0.29 (+1.09%)
Nuveen Small Cap Select’s quoted price sits in the upper half of its reported 52-week range, 14.43% below the high.
$19.93+$0.01 (+0.03%)
Alpha Architect Merlyn.AI Best-of-Breed Core Momentum ETF’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$23.44-$0.40 (-1.67%)
Global Beta Smart Income ETF’s quoted price sits in the lower half of its reported 52-week range, 0.24% below the high.
$44.16+$0.12 (+0.26%)
Syntax Stratified MidCap’s quoted price sits in the upper half of its reported 52-week range, 3.08% below the high.
